publication date: Dec. 22, 2010

In this issue: 

Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.

Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.

ImClone Protocol Generates More Questions Than Answers.

Phase III Trial Would Give Clearer Picture Of C225 Role.

Thomas Jordan To Help ASCO Enhance International Relations, Retires From BMS.

Levine Leaves Presidency Of Rockefeller University.

Download (PDF 351KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.